The diagnosis of rapidly progressive dementias (RPDs), particularly sporadic Creutzfeldt-Jakob disease (sCJD), can prove challenging. Treatable RPDs might mimic sCJD, which is currently untreatable. A recent review of a large cohort of patients with suspected CJD highlights the extent of misdiagnosis and possible sources of error.
The researchers found that approximately one-third of cases did not have prion disease, with Alzheimer disease and vascular demen tia being the most common conditions among these patients. Using additional infor mation from the clinical records of this sub group, Chitravas et al. further identified that approximately one-quarter of the patients who did not have prion disease had treat able diseases that might have been amenable to life-saving or life-extending therapy. These diseases included immune-mediated disorders such as primary angiitis of the CNS, neoplastic illness such as lymphoma, and infectious and metabolic disorders. This important paper adds to the literature regarding conditions that can cause an RPD and encourages clinicians to perform a comprehensive work-up before diagnosing a condition for which no disease-modifying therapy is currently available.
The differential diagnosis of RPDs, particu larly prion disease, can be difficult. The process is generally long and patients typi cally require extensive work-up, with multi ple diagnostic tests being performed in parallel, often in an inpatient setting.
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As Chitravas et al. note, 4 the most widely used diagnostic criteria 5 were designed by the WHO for postmortem diagnosis in epidemiological studies when pathological diagnosis is not available, and not for early diagnosis of sCJD. The diagnostic utility of cerebrospinal fluid (CSF) biomarkers -includ ing 14-3-3 protein, neuron-specific enolase, S100β, and total tau-is controversial. Importantly, Chitravas et al. found that more than 50% of patients with treatable dementias had a positive CSF 14-3-3 protein test, further illustrating the danger in relying on this test for CJD diagnosis. 4 Currently, findings from diffusionweighted imaging (DWI) and apparent diffusion coefficient MRI-including signal abnor malities in the cortical ribbon and deep nuclei-seem to have the greatest sensi tivity and specificity for the diagnosis of sCJD. 6, 7 In the recent study, 4 only three of the treatable cases (all metabolic disorders) had DWI abnormalities that overlapped with those observed in sCJD, although other MRI features not consistent with sCJD were also present. This finding provides further support for the suggestion that imaging should be incorporated in diagnostic criteria, 6, 7 and that clinicians should be wary of making a diagnosis of sCJD in cases without typical imaging abnormalities.
The inclusion of MRI results in diagnostic criteria has improved our ability to diagnose prion disease premortem. 6, 7 However, many CJD cases are not diagnosed initially, because the MRI findings in CJD, which occur early in the disease course, are often missed. Thus, not only are non-prion diseases mistaken for CJD, as the current study shows 4 but, in our experi ence, the converse is also true: some CJD cases go undiagnosed. 8 Other conditions can be mistaken for prion disease for various reasons. The time of demen tia onset is often considerably earlier than initially reported by the family of the patient. A slow, subtle decline in cognitive func tion might occur over years-suggestive of other typical dementias such as Alzheimer dis ease, Parkinson disease with dementia, and dementia with Lewy bodies-before a more-rapid deteriora tion. In cases of true RPDs, clinicians might not have a sufficiently broad dif feren tial. For example, among refer rals for suspected prion disease to RPD units, alternative diagnoses that are frequently found include other neuro degenerative dis eases, autoimmune condition s and toxic-metabolic disorders. [1] [2] [3] 9 The study by Chitravas and colleagues 4 largely corroborates the findings of other studies regarding incorrect diagnoses of sCJD, 1,2,9 and adds some new diseases to con sider in the differential diagnosis. The exten sive pathology-confirmed sam ple gathered by the NPDPSC from across the USA is a great strength of the study. The exclusive reliance on pathology-proven sam ples, however, is also a study limitation. Unfortunately, many patients mis diag nosed with prion disease do not come to autopsy, and would not, therefore, be included in this type of study. For example, patients with neurodegenerative disease would probably survive longer than the time frame of the study, and patients with auto immune disease might have a longer, fluctuating disease course and could even recover spontaneously. To accurately assess the frequency of mis diagnosis in suspected prion disease cases, a study would need to include all patients in whom a diagnosis of sCJD is made, rather than only those who come to autopsy.
A lack of access to complete medical records represents another limitation of the study. As the authors note, 4 clinical and imaging data were often not available. This missing information also limited the authors' knowledge of the referring physicians' thought processes. As mentioned in the paper, some referring physicians might have availed themselves of the NPDPSC's extensive services for difficult cases of RPD when they felt that prion disease was not a likely diagnosis, but merely a possibility. This situation might be particularly true for locations where brain autopsy and/ or neuropathology studies are difficult to perform. Thus, some of the non-prion diseases identified in this study-such as hereditary diffuse leukoencephalopathy with spheroids, Huntington disease and Marchiafava-Bignami disease-although The fact that many of the non-prion diagnoses in the present study were potentially treatable RPDs should prompt thorough diagnostic testing in patients who are suspected of having sCJD, in order to rule out mimics. The use of CSF testing, contrastenhanced MRI, and autoimmune antibody screening is supported by this study. New diagnostic tests for detection of prions in the CSF (and other bodily fluids) are being developed and could greatly improve premortem diagnostic accuracy, as they seem to have a high specificity-although a lower sensitivity than MRI-for CJD. 10 Future studies could aid the development of new premortem diagnostic criteria by including a more-complete clinical picture, such as a thorough examination of medical records, and detailed imaging and other biomarker studies. Improved criteria and diagnostic tests would increase the confidence of clini cians in differentiating prion disease from other RPDs, with sufficient specificity to avoid misdiagnosing patients with tr eatable conditions. Motor function and quality of life (QOL) can be improved substantially in some patients with Parkinson disease (PD) by treat ment with subthalamic nucleus deep brain stimulation (STN DBS), but a minority of patients can develop cognitive and emotional difficulties after surgery. Now, Smeding and colleagues report on predictors of the cogni tive and psychosocial effects of STN DBS in patients with PD. 1 These new findings are especially welcome because they move neuropsychology a step forward and help clinicians in predicting cognitive outcome 12 months after STN DBS surgery.
Smeding and colleagues compared motor, QOL, cognitive and mood changes in 105 patients with PD who were treated with STN DBS and 40 non-operated patients with PD, at baseline and after 12 months. 1 Consis tent with prior reports, the re searchers found a 41% improvement in off-phase motor scores after STN DBS. QOL improve ment was markedly greater in the STN DBS group than in the control group, and notable improvement was observed in 32% of treated individuals. These gains in motor func tion and QOL were, how ever, accompa nied by cognitive and mood deteriora tion in a sizeable minority of patients. Compared with the control group, the treat ment group had greater declines in verbal fluency, ver bal memory, overall level of cognitive func tion, and visuospatial reason ing, and on some tests of attention and process ing speed. Only one verbal fluency test decline was of a large effect size; other effects, despite their statistic al significance, were small to moderate.
Multivariate analyses revealed that 36% of patients treated with STN DBS had cognitive decline. This parameter was not associated with QOL; indeed, nine patients reported QOL improvements despite cognitive decline (the incidence of diminished QOL among the 29 other patients who experienced cognitive decline was not reported). Cognitive decline in these patients was predicted by increased patient age, impaired attention (on the basis of Trail-Making Test Part B and Stroop Color Word Interference test), and low preoperative levodopa response. Simultaneous consideration of these variables is especially relevant for the clinician. For example, at age 55 years, impairments on the attention composite (defined by a score 2 SDs below the mean) and 30% levodopa response were associated with a 70% probability of cognitive decline. By contrast, in the same age group, a similar attention impairment in the presence of a 70% levodopa response was associated with only a roughly 30% probability of cognitive decline. Similar trends with the same predictors were amplified at age 65 years.
